dpp-4 inhibitor with glp-1 receptor agonist combination not recommended ada GLP-1-RA and inhibitors in the management of type 2 diabetes Dipeptidyl peptidase-4 inhibitor - Wikipedia

3 - PMID 40934115 - Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity, NEJM (2025)

"Mechanisms of Action and Therapeutic Application of GLP-1 Receptor Agonists." Cell Metabolism

The proposed mechanisms by which GLP-1 receptor agonists might influence pancreatic health involve several biological pathways, though none have been conclusively proven to cause pancreatitis in humans

After experiments, to confirm whether the surgical vagotomy was successful, an increase in stomach weight, a reported phenotype of subdiaphragmatic vagotomy 55 , was checked

D., Seeley, R

In a propensity score matching study, there was considerable overlap between the doses of oral semaglutide 7 and 14 mg and sc semaglutide 0.5 and 1.0 mg, respectively [58]